頁籤選單縮合
題名 | 補體抑制劑Eculizumab=Complement Inhibitor Eculizumab |
---|---|
作者姓名(中文) | 蔡憶萱; 楊璦瑜; | 書刊名 | 藥學雜誌 |
卷期 | 35:2=139 2019.06[民108.06] |
頁次 | 頁59-64 |
分類號 | 418.23 |
關鍵詞 | 補體抑制劑; 陣發性夜間血紅素尿症; 非典型溶血性尿毒症候群; Eculizumab; |
語文 | 中文(Chinese) |
中文摘要 | Eculizumab 是重組人類源的單株抗體,結合 C5的補體蛋白。為第一個用於治療 補體介導疾病的標靶補體抑制劑,已核准用於陣發性夜間血紅素尿症和非典型溶血 性尿毒症候群。由於 eculizumab 抑制補體的免疫作用,會增加感染的風險,特別是 Neisseria spp.。建議在給予 eculizumab 前須接種腦膜炎疫苗與預防性抗生素。 |
英文摘要 | Eculizumab is a recombinant humanized monoclonal antibody that binds to C5 complement protein. It is the first targeted complement inhibitor approved for the treatment of complement-mediated diseases, including paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). Eculizumab inhibits complement Immune effect, the risks of potentially life-threatening infections, notably with Neisseria spp. Thus, vaccination and prophylaxis antibiotic with a meningococcal vaccine prior to administration of eculizumab is recommended. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。